Effect of treatment of overt hypothyroidism on insulin resistance

Aml Mohamed Nada

Aml Mohamed Nada, Department of Internal Medicine, Unit of Endocrinology, Diabetes and Metabolism, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. Correspondence to: Dr. Aml Mohamed Nada, MD, Lecturer, Department of Internal Medicine, Unit of Endocrinology, Diabetes and Metabolism, Faculty of Medicine, Mansoura University, El-Gomhoria Street, Mansoura 35516, Egypt. aml-nadanoha@yahoo.com

Abstract
AIM: To investigate the impact of hypothyroidism and thyroxine therapy on insulin sensitivity in patients with overt hypothyroidism.

METHODS: The study included twenty seven overtly hypothyroid and fifteen healthy euthyroid South Western Asian females. Both groups had matching age and body mass index. Physiological and pathological conditions as well as medications that may alter thyroid function, glucose homeostasis or serum lipids were ruled out. Serum thyrotropin (TSH), free tetraiodothyronine (FT4), free triiodothyronine (FT3), fasting insulin (FI), fasting plasma glucose (FPG), total cholesterol and triglycerides were measured before and six months after initiating thyroxine therapy for hypothyroid patients and once for the control group. Insulin resistance (IR) was estimated using homeostasis model assessment (HOMA-IR) and Body mass index (BMI) was calculated.

RESULTS: Both study groups, hypothyroid patients and euthyroid control subjects, had matching age and body mass index (P-value 0.444, 0.607 respectively). No significant difference was found between the hypothyroid patients and the euthyroid control group regarding fasting plasma glucose, fasting insulin, insulin resistance, total cholesterol and triglycerides (P-values 0.432, 0.621, 0.883, 0.586, 0.05 respectively). In the hypothyroid patients, triglycerides showed direct correlation to TSH and inverse correlation to FT3. Similarly total cholesterol inversely correlated to FT3 but its direct correlation to TSH did not reach statistical significance. After thyroxine replacement and reaching an euthyroid state as confirmed by clinical and laboratory data, there was no significant change in fasting plasma glucose, insulin resistance or triglyceride level (P-value 0.216, 0.204, 0.175 respectively) while total cholesterol significantly decreased (P-value 0.043) and fasting insulin significantly increased (P-value 0.047).

CONCLUSION: Hypothyroidism has no impact on insulin sensitivity. Correction of hypothyroidism is not associated with a significant change of insulin sensitivity or triglycerides, but with a significant reduction of total cholesterol.

© 2013 Baishideng. All rights reserved.

Key words: Hypothyroidism; Female; Thyroxine; Insulin resistance; Triglycerides; Cholesterol

Core tip: Thyroid dysfunction is the second most common endocrine disorder after diabetes mellitus. Both diseases are strongly associated. Hypothyroidism is claimed to cause insulin resistance. Some available reports are in agreement and others are against this suggestion. In our study, we did not find a significant effect of hypothyroidism or thyroxine replacement on insulin resistance as calculated by insulin resistance was estimated using homeostasis model assessment. Thyroxine therapy leads to a significant reduction of total cholesterol but it does not change triglycerides. This may partially explain the association between hypothyroidism and dyslipidaemia as well as cardiovascular risk.
INTRODUCTION

Thyroid dysfunction and diabetes mellitus (DM) are the two most common endocrine disorders. Both disorders appear to be closely linked[3,4]. A recent meta-analysis that was conducted on available data in 10920 patients with DM revealed a 11% prevalence of thyroid disease with no difference between type 1 DM and type 2 DM. The prevalence in women was consistently more than two-folds that in men[5].

It has also been postulated that insulin secretion is regulated by the thyroid hormone[6,7] and diabetes risk is related to thyroid hormone levels[6,8]. The initial event of glucose-stimulated insulin secretion is glucose sensing. The glucose transporter 2 (GLUT2) and glucokinase (GK) are key molecules which affect various processes of glucose sensing in pancreatic β-cells[7]. Impairment in glucose sensing contributes to pancreatic β-cell dysfunction. Therefore, it is necessary to maintain adequate expression levels of GLUT2 and GK to ensure normal β-cell function[6]. Triiodothyronine (T3) can modulate the expression of GLUT2 and GK mRNAs and proteins in pancreatic islets[6] and liver[7].

To date, only a few studies have investigated the effect of hypothyroidism and its recovery by thyroid hormone treatment on glucose metabolism and lipid profile, and the results have been controversial. Some researchers elucidated lower insulin sensitivity in patients with overt hypothyroidism which improved after thyroxine treatment[8,9]. Subclinical hypothyroidism was also encountered as a cause of insulin resistance and its related dyslipidaemia in patients with rheumatoid arthritis[10]. Contrary to that, Brenta et al[11] did not find significant differences in insulin sensitivity or lipid profile before and after thyroxine replacement in subclinical hypothyroidism.

In the light of existing data, we decided to study the impact of hypothyroidism on insulin sensitivity in overtly hypothyroid patients and to investigate the possible effect of thyroxine replacement on insulin sensitivity, triglycerides and total cholesterol in those populations.

MATERIALS AND METHODS

This study was approved by the Research and Ethics Committee of Asir Central Hospital and written informed consents were acquired from all participants.

Forty-two South Western Asian females were recruited from the endocrine clinic in a tertiary care hospital in southern region of Saudi Arabia, during January 2010 and December 2011. They included twenty seven patients with overt hypothyroidism and fifteen healthy euthyroid control women with matching age and body mass index (BMI). Full history taking and clinical examination were done for all participants. The inclusion criteria were: adult, premenopausal females, who were newly diagnosed with overt hypothyroidism. Exclusion criteria were diabetes, polycystic ovarian disease, liver disorders, renal disorders, congestive cardiac failure or any other systemic illness. In addition, pregnancy and lactation, intake of oral contraceptive pills, statins and other medications that may alter thyroid functions, glucose homeostasis or serum lipids also accounted for exclusion from the study.

After an overnight fasting, blood samples were collected from all participants for measuring biochemical parameters. Thyroid profile (TSH, FT4 and FT3), fasting insulin, fasting plasma glucose, total cholesterol and triglycerides were measured, before and six months after initiating thyroxine therapy and reaching an euthyroid state for hypothyroid patients. These parameters were measured once for the euthyroid control group.

Insulin resistance (IR) was estimated using HOMA-IR, IR = FPG in milli-gram per deciliter × FI in micro-international unit per milli-litre/405[15,16]. BMI was calculated by dividing weight of the patient in kilograms by square the height of the patient in meters[17].

Thyroid profile and insulin level were estimated by Advia centaur auto-analyzer Siemens using chemiluminescent technology. Fasting plasma glucose and triglycerides were measured by bichromatic technique while cholesterol was measured by polychromatic technique. Normal ranges for all parameters: TSH: 0.27-4.2 μIU/mL, FT4: 12-22 pmol/L, FT3: 3.9-6.8 pmol/L, FI: 2.6-37.6 μIU/mL, total cholesterol: 50-200 mg/dL, triglycerides: 30-150 mg/dL[18-20].

Statistical analysis

Collected data were analyzed using the Statistical Package for Social Sciences (SPSS ver. 19). Descriptive statistics (i.e., mean and standard deviation) were applied. Pearson’s Correlation Coefficients (r) between study variables were calculated. Significant P-values were considered at < 0.05.

RESULTS

Our study population consisted of 42 females; 27 patients with overt hypothyroidism and 15 euthyroid healthy participants. The two groups had matching age and body mass index (33.12 ± 10.4 vs 35.67 ± 9.1, P = 0.44, 31.11 ± 6.78 vs 32.24 ± 6.68, P = 0.61 respectively). Fasting insulin, FPG, IR, total cholesterol and triglycerides did not show significant difference in hypothyroid patients as compared to the euthyroid group (P-values 0.432, 0.621, 0.883, 0.586, 0.05 respectively) as shown in Table 1.

In the hypothyroid state, Triglycerides directly correlated to TSH and inversely to FT3 (P-value 0.009, 0.001 respectively). Total cholesterol inversely correlated to FT3 (P-value 0.029) and was directly proportionate to TSH although this relation did not reach statistical significance (P-value = 0.327) as shown in Table 2.
Hypothyroidism is known to be associated with normal or high levels of triglycerides\(^2\). In our study, triglycerides in the hypothyroid patients did not differ significantly from the euthyroid control with direct proportion to TSH and inverse proportion to FT3\(^3\). Triglycerides did not significantly change after thyroxine replacement. This is in agreement with reports of several studies, which showed that triglycerides might be normalized or remain unchanged after treatment, suggesting a more complex cause of dyslipidaemia in hypothyroidism\(^4\).

Total cholesterol inversely correlated to FT3 in the hypothyroid patients with a significant decrease after thyroxine therapy. This is consistent with results obtained by Melpomeni et al who found that restoration of an euthyroid state in hypothyroid patients was associated with a significant reduction in total cholesterol\(^5,6\). Our findings are also consistent with those demonstrated in several other studies\(^7,8,9\).

The presence of some variations among different studies regarding the association between hypothyroidism and disturbed lipid profile may be explained by the variable effects of hypothyroidism on lipids according to the

### Table 1 Laboratory and anthropometric parameters in hypothyroid patients versus euthyroid subjects

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Hypothyroid (mean ± SD)</th>
<th>Euthyroid (mean ± SD)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>33.2 ± 10.4</td>
<td>35.7 ± 9.1</td>
<td>0.444</td>
</tr>
<tr>
<td>BMI</td>
<td>31.1 ± 6.8</td>
<td>32.2 ± 6.7</td>
<td>0.607</td>
</tr>
<tr>
<td>TSH</td>
<td>22.4 ± 3.62</td>
<td>2.9 ± 1.5</td>
<td>0.010</td>
</tr>
<tr>
<td>FT4</td>
<td>11.2 ± 4.0</td>
<td>13.7 ± 2.1</td>
<td>0.013</td>
</tr>
<tr>
<td>FT3</td>
<td>4.4 ± 1.0</td>
<td>4.5 ± 0.5</td>
<td>0.557</td>
</tr>
<tr>
<td>FPG</td>
<td>93.5 ± 14.7</td>
<td>89.8 ± 13.9</td>
<td>0.432</td>
</tr>
<tr>
<td>FI</td>
<td>10.6 ± 8.1</td>
<td>11.8 ± 6.3</td>
<td>0.621</td>
</tr>
<tr>
<td>IR</td>
<td>2.5 ± 2.1</td>
<td>2.6 ± 1.5</td>
<td>0.883</td>
</tr>
<tr>
<td>TG</td>
<td>144.8 ± 85.4</td>
<td>97.9 ± 36.1</td>
<td>0.050</td>
</tr>
<tr>
<td>TCH</td>
<td>195.0 ± 37.9</td>
<td>189.0 ± 29.9</td>
<td>0.586</td>
</tr>
</tbody>
</table>

BMI: Body mass index; TSH: Thyrotropin; FPG: Fasting plasma glucose; FT: Fasting insulin; IR: Insulin resistance; FT4: Free tetraiodothyronine; FT3: Free triiodothyronine; TG: Triglycerides; TCH: Total cholesterol.

### Table 2 Correlation between different variables before and after thyroxine replacement

<table>
<thead>
<tr>
<th>Variable</th>
<th>Before treatment (mean ± SD)</th>
<th>After treatment (mean ± SD)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>31.1 ± 6.8</td>
<td>31.4 ± 7.2</td>
<td>0.485</td>
</tr>
<tr>
<td>TSH</td>
<td>22.4 ± 3.62</td>
<td>2.9 ± 1.5</td>
<td>0.010</td>
</tr>
<tr>
<td>FT4</td>
<td>11.2 ± 4.0</td>
<td>13.7 ± 2.1</td>
<td>0.013</td>
</tr>
<tr>
<td>FT3</td>
<td>4.4 ± 1.0</td>
<td>4.5 ± 0.5</td>
<td>0.557</td>
</tr>
<tr>
<td>FPG</td>
<td>93.5 ± 14.7</td>
<td>90.2 ± 12.2</td>
<td>0.216</td>
</tr>
<tr>
<td>FI</td>
<td>10.6 ± 8.1</td>
<td>13.6 ± 7.3</td>
<td>0.047</td>
</tr>
<tr>
<td>IR</td>
<td>2.5 ± 2.1</td>
<td>3.0 ± 1.9</td>
<td>0.204</td>
</tr>
<tr>
<td>TG</td>
<td>144.8 ± 85.4</td>
<td>128.1 ± 64.8</td>
<td>0.175</td>
</tr>
</tbody>
</table>

BMI: Body mass index; TSH: Thyrotropin; FPG: Fasting plasma glucose; FT: Fasting insulin; IR: Insulin resistance; FT4: Free tetraiodothyronine; FT3: Free triiodothyronine; TG: Triglycerides; TCH: Total cholesterol.

### Table 3 Comparison between different variables before and after thyroxine replacement

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before treatment (mean ± SD)</th>
<th>After treatment (mean ± SD)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>31.1 ± 6.8</td>
<td>31.4 ± 7.2</td>
<td>0.485</td>
</tr>
<tr>
<td>TSH</td>
<td>22.4 ± 3.62</td>
<td>2.9 ± 1.5</td>
<td>0.010</td>
</tr>
<tr>
<td>FT4</td>
<td>11.2 ± 4.0</td>
<td>13.7 ± 2.1</td>
<td>0.013</td>
</tr>
<tr>
<td>FT3</td>
<td>4.4 ± 1.0</td>
<td>4.5 ± 0.5</td>
<td>0.557</td>
</tr>
<tr>
<td>FPG</td>
<td>93.5 ± 14.7</td>
<td>90.2 ± 12.2</td>
<td>0.216</td>
</tr>
<tr>
<td>FI</td>
<td>10.6 ± 8.1</td>
<td>13.6 ± 7.3</td>
<td>0.047</td>
</tr>
<tr>
<td>IR</td>
<td>2.5 ± 2.1</td>
<td>3.0 ± 1.9</td>
<td>0.204</td>
</tr>
<tr>
<td>TG</td>
<td>144.8 ± 85.4</td>
<td>128.1 ± 64.8</td>
<td>0.175</td>
</tr>
</tbody>
</table>

BMI: Body mass index; TSH: Thyrotropin; FPG: Fasting plasma glucose; FT: Fasting insulin; IR: Insulin resistance; FT4: Free tetraiodothyronine; FT3: Free triiodothyronine; TG: Triglycerides; TCH: Total cholesterol.

**Discussion**

The association between hypothyroidism and diabetes mellitus had raised great interest in studying the mechanism of this association. Many studies targeted the influence of hypothyroidism on insulin sensitivity as the main underlying pathophysiology of this relation. Despite the many studies, results are conflicting with several studies reporting that hypothyroidism is a state of increased insulin resistance\(^12\).

In our study, there was no significant difference between the hypothyroid patients and the euthyroid healthy group regarding fasting insulin, FPG and insulin resistance. This is consistent with results of a study conducted by Giménez-Palop et al\(^24\) on 17 hypothyroid women compared to 20 euthyroid control women.

Similarly, Owecki et al\(^23\) did not find a significant difference in insulin sensitivity between hypothyroid patients and euthyroid participants.

Neither FPG nor insulin resistance as calculated by HOMA-IR significantly changed after thyroxine replacement and reaching an euthyroid state as per clinical and laboratory evidence. There was a significant increase in the fasting insulin as compared to the pretreatment level but this was not statistically significant when compared to the euthyroid control (13.55 ± 7.25 or 11.82 ± 6.31, P = 0.445) and it did not affect the overall calculated insulin resistance. This is again in agreement with results demonstrated by Giménez-Palop et al\(^24\) although the increase in insulin levels in his study did not reach a statistical significance.

Referring to our study and studies in agreement with our findings, we can say that the association between hypothyroidism and T2DM may be attributed to a complex interplay\(^26\). It may depend on the severity of hypothyroidism\(^27\). There may be direct genetic links between thyroid diseases and T2DM as suggested by few studies. These studies suggest that homozygosity of polymorphism of the deiodinase type 2 (DIO2) gene, Thr92Ala is associated with an increased risk of T2DM\(^28\). Thyroid hormones may also affect glucose and lipid homeostasis via central effects at the level of the hypothalamus\(^29\).
severity of hypothyroidism in the studied groups of patients as evidenced by Sunanda et al. Sunanda et al. studied the lipid profile in hypothyroid patients with different degrees of hypothyroidism and concluded that the effect of hypothyroidism on the serum lipids is more marked in patients with higher TSH levels.

So, the association between hypothyroidism and cardiovascular risk may be attributed to the dyslipidaemic effect of hypothyroidism, underlying genetic factor or there may be another complex underlying mechanism that deserves further studies.

In conclusion, our study suggests that hypothyroidism has no impact on insulin sensitivity in overtly hypothyroid females of South Western Asian ethnicity. Thyroxine therapy does not cause significant change in insulin sensitivity in this ethnic group. So, other mechanisms that may explain the strong association between hypothyroidism and T2DM may exist. Although total cholesterol and triglycerides are not significantly higher in hypothyroid patients, thyroxine treatment leads to a significant reduction in total cholesterol without a significant effect on triglycerides. This may partially explain the association between hypothyroidism and cardiovascular risk.

**REFERENCES**


19. Pesce AJ, editors. Clinical chemistry: theory, analysis, and


29 The Interface between thyroid and diabetes mellitus. _Clin Endocrinol (Oxf)_ 2011 Feb 24; [Epub ahead of print] [PMID: 21521298 DOI: 10.1111/j.1365-2265.2011.04029.x]


32 Krauss RM, Levy RI, Fredrickson DS. Selective measurement of two lipase activities in postheparin plasma from normal subjects and patients with hyperlipoproteinemia. _J Clin Invest_ 1974; 54: 1107–1124 [PMID: 4357095 DOI: 10.1172/JCI107855]


34 Tzotzas T, Krassas GE, Konstantinidis T, Bougouli M. Changes in lipoprotein(a) levels in overt and subclinical hyperthyroidism before and during treatment. _Thyroid_ 2000; 10: 803–808 [PMID: 11041458 DOI: 10.1089/thy.2000.10.803]

35 de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW. Lipoprotein(a) and apolipoprotein B plasma concentrations in hyperthyroid, euthyroid, and hyperthyroid subjects. _J Clin Endocrinol Metab_ 1990; 76: 121–126 [PMID: 241075 DOI: 10.1210/jc.76.1.121]


40 Pazos F, Alvarez JJ, Rubiès-Prat J, Varela C, Lasunción MA. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. _J Clin Endocrinol Metab_ 1995; 80: 562–566 [PMID: 7852521 DOI: 10.1210/jc.80.2.562]


47 P-Reviewers Mortensen O, Sasaoka T S-Editor Wen LL L-Editor A E-Editor Lu Y